Is Zyloprim affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
Zyloprim is affected by pharmacogenetics through the ABCG2 gene. Your genotype for this gene can change how well Zyloprim works for you or how well you tolerate it. The strongest evidence level on this page is Moderate, from the published guidelines shown below.
What's in Zyloprim
Allopurinol Affected by ABCG2
Affected by ABCG2. Guidance from DPWG, moderate evidence.
Read the full allopurinol genetics guideAllopurinol phenotype recommendations
Published guidance from DPWG on how allopurinol should be dosed or substituted based on your ABCG2 phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Normal FunctionABCG2 | Your ABCG2 genotype does not change how you respond to allopurinol; standard dosing applies. | DPWG Use standard allopurinol dosing. |
Moderate |
| Decreased FunctionABCG2 | This drug may lower your uric acid a little less than usual. You may need a somewhat higher dose. | DPWG Use 1.25 times the standard allopurinol dose. Equivalent titration schedule: 100, 200, 400, 500 mg/day instead of the usual 100, 200, 300, 400 mg/day. |
Moderate |
| Poor FunctionABCG2 | This drug may lower your uric acid less than usual. You may need a higher dose to reach your target level. | DPWG Use 1.4 times the standard allopurinol dose. Equivalent titration schedule: 100, 300, 400, 600, 700 mg/day instead of the usual 100, 200, 300, 400, 500 mg/day. |
Moderate |
| IndeterminateABCG2 | We couldn't read your ABCG2 result, so we can't say how this drug will work for you. | DPWG Use standard allopurinol dosing and titrate to target uric acid concentration. |
Not rated |
| Not availableABCG2 | We do not have an ABCG2 result for you, so we cannot personalize guidance for allopurinol. | DPWG Use standard allopurinol dosing and titrate to target uric acid concentration. |
Not rated |
Source: DPWG
The gene behind the guidance
ABCG2 ATP-Binding Cassette Subfamily G Member 2 (BCRP)
ABCG2 is a transporter that moves urate and several drugs out of cells. The Q141K variant (rs2231142) is common, particularly in East Asian populations, and reduces transporter function. Carriers tend to have higher serum urate and respond less to allopurinol, and the Dutch Pharmacogenetics Working Group advises a higher allopurinol dose for them. ABCG2 also affects how quickly the body clears rosuvastatin.
The DPWG advises 1.25 times the standard allopurinol dose for one copy of Q141K and 1.4 times for two.
See all drugs affected by ABCG2Browse the full drug class: Gout treatment.
Find out how your genetics affect Zyloprim
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.